Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL152870 | 0.91 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MAPTCYP11B1 | |
| SCHEMBL146559 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTCYP11B1 | |
| Hydrochloric Acid SCHEMBL28148550 | 0.85 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MAPTCYP11B1 | |
| SCHEMBL913315 | 0.84 | HPGDS (0.58) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL29578423 | 0.84 | HPGDS (0.58) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL25118611 | 0.84 | HPGDS (0.58) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL903715 | 0.84 | HPGDS (0.58) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL12523550 | 0.84 | HPGDS (0.58) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL20370130 | 0.84 | CYP11B1 (0.65) | CYP11B1CYP11B2CYP3A4HPGDS | |
| SCHEMBL803150 | 0.83 | RAB9A (0.69) | NPC1RAB9ASMN1; SMN2MAPTCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230209990-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-10672996-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230209990-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L3MBTL3, AGO2, ELAVL3 | NPC1 1321/4885RAB9A 478/4885SMN1; SMN2 3342/4885 |
| US-10672996-B2 | Organic electroluminescent materials and devices | ORC3, EML4, EPCAM | NPC1 2913/4885RAB9A 2216/4885SMN1; SMN2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.